Roche Holding AG Virtual Investor Event at EASD Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Harry Sephton - UBS Limited - Analyst : So my first question is on the side effect profile for CT-388. So we've seen in the past, as you showed that with faster titrations, you do see high rates of nausea and vomiting. But I think in your study, you could quite clearly see the rates of constipation and diarrhea did seem to be more prominent with CT-388 than we've seen with other studies. And that didn't necessarily improve at lower doses. Do you have an explanation for that? Or how manageable do you think that is?

Question: Harry Sephton - UBS Limited - Analyst : Okay. And maybe if I could just ask on 996 as well. So for the slower dose titration cohort, there did seem to be limited efficacy on weight loss. So albeit this being in a very small number of patients, given the commentary you said around trying to push the titration to the limit on the other cohorts, is the lack of efficacy in that slower titration cohort a potential issue? Or have you seen anything that sort of better explains why it didn't work so well in that cohort?